Shire (NASDAQ:SHPG) had its price target decreased by stock analysts at SunTrust Banks to $190.00 in a note issued to investors on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks’ target price indicates a potential upside of 51.96% from the company’s previous close. SunTrust Banks also issued estimates for Shire’s FY2018 earnings at $15.20 EPS.
Several other research firms have also weighed in on SHPG. ValuEngine lowered Shire from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research lowered Shire from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Cantor Fitzgerald set a $222.00 price target on Shire and gave the company a “buy” rating in a research report on Wednesday, February 14th. FBR & Co reissued a “buy” rating and set a $201.00 price target on shares of Shire in a research report on Monday, October 30th. Finally, Royal Bank of Canada dropped their price target on Shire to $181.00 and set an “outperform” rating on the stock in a research report on Friday, February 16th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $204.00.
Shire (SHPG) opened at $125.03 on Tuesday. The firm has a market capitalization of $38,640.00, a price-to-earnings ratio of 9.13, a P/E/G ratio of 0.75 and a beta of 1.41. Shire has a 52-week low of $123.73 and a 52-week high of $192.15. The company has a current ratio of 0.98, a quick ratio of 0.52 and a debt-to-equity ratio of 0.55.
Shire (NASDAQ:SHPG) last posted its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share for the quarter, beating the consensus estimate of $3.86 by $0.12. The firm had revenue of $4.14 billion for the quarter. Shire had a return on equity of 14.75% and a net margin of 28.17%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the firm posted $3.37 earnings per share. equities analysts predict that Shire will post 15.27 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the business. SeaCrest Wealth Management LLC purchased a new position in Shire in the fourth quarter valued at about $107,000. Avestar Capital LLC bought a new stake in shares of Shire during the 4th quarter worth about $116,000. Amica Retiree Medical Trust bought a new stake in shares of Shire during the 4th quarter worth about $120,000. BB&T Investment Services Inc. boosted its stake in shares of Shire by 1,672.3% during the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 786 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC bought a new stake in shares of Shire during the 3rd quarter worth about $159,000. Hedge funds and other institutional investors own 20.92% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/02/22/shire-shpg-price-target-cut-to-190-00-by-analysts-at-suntrust-banks.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.